11th AACR JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision Medicine

Transcription

1 11th AACR JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision Medicine Friday, Feb. 8 Saturday, Feb. 9 Sunday, Feb. 10 Monday, Feb. 11 Tuesday, Feb :30 20:00 Welcome and Keynote Session 8:00 Plenary Session 1 : Tumor Microenvironment 8:00 Plenary Session 4: Metabolism 8:00 Plenary Session 7: Microbiome 8:00 Plenary Session 10: Drug Resistance 20:00 21:30 Opening Reception 10:00 Plenary Session 2: Cancer Precision Medicine, Prevention, Interception, and Early Detection 10:00 Plenary Session 5: Epigenetics 10:00 Plenary Session 8: Engineering, Nanotechnology, and Imaging 10:00 Plenary Session 11: Novel Targets and Drug Discovery 16:00 Plenary Session 3: Heterogeneity, Clonal Evolution, and Big Data 16:00 Plenary Session 6: Immunotherapy 16:00 Plenary Session 9: Liquid Biopsy 16:00 Plenary Session 12: Clinical Research and Clinical Trials 1 Poster Session A Includes Abs Poster Session B Includes Abs Poster Session C Includes Abs Poster Session D Includes Abs Categories: 1 Categories: 1 Categories: 1 Categories: Tumor microenvironment Metabolism Microbiome Clinical research and clinical trials Heterogeneity and clonal evolution Big data Cancer precision medicine, prevention, interception, and early detection Epigenetics Engineering and nanotechnology Drug resistance Immunotherapy (including immunogenomics and the immune microenvironment) Imaging Novel targets and drug discovery Genomics Liquid biopsy Cancer Biology Part 3 Other Cancer Biology Part 2 Cancer Biology Part 1 Cancer Biology travel constraints

2 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine Friday, Feb. 8, 2019 Welcome and Keynote Session 6:30-8:00 p.m. Cancer genomics: Discovery to clinical translation Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio Regulatory T cells in tumor immunity Shimon Sakaguchi, Osaka University, Osaka, Japan Opening Reception 8:00- p.m. Saturday, Feb. 9, 2019 Plenary Session 1: Tumor Microenvironment 8:00- a.m. Exploiting the biology of exosomes for diagnosis and treatment of cancer Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas Role of actin dynamics in cell fate plasticity of microenvironmental cells Hideyuki Saya, Keio University School of Medicine, Tokyo, Japan Neutrophil extracellular traps activated during inflammation awaken dormant cancer cells Mikela Egeblad, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York Plenary Session 2: Cancer Precision Medicine, Prevention, Interception, and Early Detection 10:00- a.m. Non-invasive earlier detection of cancer Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Construction of cancer genomic medicine platform in Japan Hiroyuki Mano, National Cancer Center Research Institute,Tokyo, Japan Genome-wide analysis of plasma cell-free DNA for cancer detection Geoffrey R. Oxnard, Dana-Farber Cancer Institute, Boston, Massachusetts 1

3 Plenary Session 3: Heterogeneity, Clonal Evolution, and Big Data 4:00-5:30 p.m. Clonal dynamics and cellular fitness in cancer to single cell resolution Samuel Aparicio, British Columbia Cancer Agency, Vancouver, Canada Strong potential for combinatorial approaches involving TGF-b kinase inhibitor: considerable utility in a wide variety of cancers Seong-Jin Kim, Seoul National University, Seoul, South Korea Additional speaker to be announced Poster Session A 5:30-7:30 p.m. Sunday, Feb. 10, 2019 Plenary Session 4: Metabolism 8:00- a.m. Title to be announced Kei-ichi Nakayama, Kyushu University, Fukuoka, Japan PI3-kinase and cancer Lewis C. Cantley, Weill Cornell Medical College, New York- Presbyterian Hospital, New York, New York NRF2 addiction in cancer cells and its impact on cancer metabolism Hozumi Motohashi, Tohoku University, Sendai, Japan Plenary Session 5: Epigenetics 10:00- a.m. Precision cancer risk diagnosis based upon epigenomic record of the life Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo, Japan Targeting chromatin regulators in cancer Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts ATAC-seq analysis reveals epigenomic heterogeneity in breast cancer Reo Maruyama, Japanese Foundation for Cancer Research Center Institute, Tokyo, Japan Plenary Session 6: Immunotherapy 4:00-5:30 p.m. Potent anti-tumor effects of IL-7/CCL19-producing CAR-T cells against solid tumors Koji Tamada, Yamaguchi University, Yamaguchi, Japan 2

4 Mechanistic basis of cancer immunotherapy Ira Mellman, Genentech, South San Francisco, California Genetic alterations involving PD-1 ligands in virus-associated lymphomas Keisuke Kataoka, National Cancer Center Research Institute, Tokyo, Japan Poster Session B 5:30-7:30 p.m. Monday, Feb. 11, 2019 Plenary Session 7: Microbiome 8:00- a.m. The role of the microbiome in response to cancer therapy Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas The impact of Helicobacter pylori infection on gastric carcinogenesis Masanori Hatakeyama, University of Tokyo, Tokyo, Japan Microbial regulation of tumor elicited inflammation Sergei Grivennikov, Fox Chase Cancer Center, Philadelphia, Pennsylvania Plenary Session 8: Engineering, Nanotechnology, and Imaging 10:00- a.m. Macrocyclic pseudo-natural peptides for anti-cancer therapies Hiroaki Suga, University of Tokyo, Tokyo, Japan Nanomedicines to improve the therapeutic index of precision medicines Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, New York Application of tissue clearing technology in cancer research Kei Takahashi, University of Tokyo, Tokyo, Japan Plenary Session 9: Liquid Biopsy 4:00-5:30 p.m. The emerging role of exosome in cancer diagnostic and therapeutics Takahiro Ochiya, Tokyo Medical University, National Cancer Center Research Institute, Tokyo, Japan Inactivation of DNA repair to improve immune surveillance and restrict cancer growth Alberto Bardelli, University of Turin - Candiolo Cancer Institute IRCCS, Candiolo, Italy A proteome-wide catalog of viable tissue-derived exosomes, toward development of cancer liquid biopsy Koji Ueda, Japanese Foundation for Cancer Research Cancer Institute, Tokyo, Japan 3

5 Poster Session C 5:30-7:30 p.m. Tuesday, Feb. 12, 2019 Plenary Session10: Drug Resistance 8:00- a.m. Mechanism of the intrinsic resistance and emergence of tolerant cells to osimertinib in EGFR mutated lung cancer Seiji Yano, Kanazawa University Cancer Research Institute, Kanazawa, Japan Synthetic lethal approaches to cancer therapy Alan Ashworth, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California Cellular diversity by genetic and non-genetic alteration in cancer induces acquired resistance in NSCLC Ryohei Katayama, Japanese Foundation for Cancer Research Cancer Institute, Tokyo, Japan Plenary Session 11: Novel Targets and Drug Discovery 10:00- a.m. Chemical strategies for discovering direct inhibitors of K-Ras and other Oncogenic GTPases Kevan Michael Shokat, University of California San Francisco and Howard Hughes Medical Institute, San Francisco, California Telomere as the starting point of anticancer drug discovery Hiroyuki Seimiya, Japanese Foundation for Cancer Research Cancer Institute, Tokyo, Japan Structure and function of mammalian SWI/SNF chromatin remodeling complexes in human cancer Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts Plenary Session 12: Clinical Research and Clinical Trials 4:00-5:30 p.m. Novel pathogenetic and therapeutic targets in diffuse large B cell lymphoma Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, New York Metabolic regulation of stemness in hematopoietic malignancy Atsushi Hirao, Kanazawa University Cancer Research Institute, Kanazawa, Japan Targeting oncogene dependencies in metastatic breast cancer: A clinical and translational perspective 4

6 Dejan Juric, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Phase II clinical trial of oncolytic herpes virus G47Δ in patients with glioblastoma Tomoki Todo, University of Tokyo, Tokyo, Japan Poster Session D 5:30-7:30 p.m. 5